指南与共识颈动脉与弓上血管

新诊断和/或失代偿性心力衰竭的无症状患者颈动脉血运重建的30天卒中/死亡率超过血管外科学会指南风险

Thirty-day stroke/mortality of carotid revascularization in asymptomatic patients with newly diagnosed and/or decompensated heart failure exceeds the Society for Vascular Society guideline risks.
指南 / 共识 · J Vasc Surg · 2025-01-19

基于美国外科医师学会国家手术质量改进计划2011至2023年数据库,无症状患者行颈动脉内膜切除术(CEA)或颈动脉支架置入术(CAS)后,新诊断和/或失代偿性心力衰竭(HF)患者的30天卒中/死亡率分别为4.83%和5.75%,均超过血管外科学会指南推荐的3%阈值。HF患者其他主要并发症风险也显著更高,作者认为对这类患者行手术血运重建应极其谨慎,可优先保守治疗。

要点

  • 无症状患者CEA后HF组30天卒中/死亡率为4.83%,高于无HF组的2.55%(P = .01)。
  • 无症状患者CAS后HF组30天卒中/死亡率为5.75%,无HF组为3.60%(P = .53)。
  • CEA后HF组心脏、肺部、肾脏并发症、脓毒症、远端栓塞、非计划手术、延长住院和30天再入院风险均更高。

核心结论

  • 对于新诊断和/或失代偿性HF合并无症状颈动脉狭窄患者,CEA和CAS术后30天卒中/死亡率风险均大大超过血管外科学会指南推荐。
  • 结合其他主要并发症风险显著更高,对无症状HF患者行手术血运重建的决定应极其谨慎,可优先保守治疗。

研究设计与样本

  • 回顾性队列研究,使用美国外科医师学会国家手术质量改进计划目标数据库2011年至2023年数据。
  • 纳入无症状行CEA或CAS的患者,HF定义为术后30天内新诊断HF和/或慢性HF急性加重。
  • 采用1:3倾向性评分匹配平衡HF与非HF患者的术前差异,CEA和CAS患者分别分析。
  • CEA共23,274例,其中601例(2.58%)有HF,匹配1,803例无HF患者;CAS共1,361例,其中87例(6.38%)有HF,匹配222例无HF患者。

主要发现

  • CEA后HF组 vs 无HF组:卒中/死亡率4.83% vs 2.55%(P = .01),心脏并发症6.66% vs 3.38%(P < .01),肺部并发症4.49% vs 2.44%(P = .02),肾脏并发症1.66% vs 0.44%(P = .01)。
  • CEA后HF组 vs 无HF组:脓毒症1.50% vs 0.44%(P = .02),远端栓塞0.50% vs 0.00%(P = .02),非计划手术5.99% vs 3.49%(P = .01),30天再入院13.14% vs 8.65%(P < .01),延长住院P < .01。
  • CAS后HF组 vs 无HF组:卒中/死亡率5.75% vs 3.60%(P = .53)。
  • HF患者合并症负担明显更高。

关键数值与推荐

  • 血管外科学会最新指南推荐:无症状个体颈动脉血运重建应在围手术期卒中/死亡率不超过3%时提供。
  • CEA后HF组30天卒中/死亡率为4.83%,超过3%阈值。
  • CAS后HF组30天卒中/死亡率为5.75%,超过3%阈值。

临床怎么用

  • 作者认为,对无症状HF患者行手术血运重建的决定应极其谨慎,可优先保守治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: According to the latest Society for Vascular Surgery guidelines, carotid revascularization for asymptomatic individuals should be offered if the perioperative stroke/death rate does not exceed 3%. Heart failure (HF) has been associated with reduced survival rates following carotid revascularization, which may significantly impact the risk-benefit decision of treating asymptomatic patients with HF. This study aimed to evaluate the 30-day postoperative risks in asymptomatic patients with newly diagnosed and/or decompensated HF undergoing carotid endarterectomy (CEA) and carotid artery stenting (CAS). METHODS: Asymptomatic patients who underwent CEA and CAS were identified in the American College of Surgeons-National Surgery Quality Improvement Program targeted databases from 2011 through 2023. HF was defined as newly diagnosed HF and/or an acute exacerbation of chronic HF within 30 days of the surgery. A 1:3 propensity-score matching was used to balance preoperative differences between patients with and without HF. Patients who underwent CEA and CAS were analyzed separately. Thirty-day postoperative outcomes were examined. RESULTS: There were 23,274 patients who underwent CEA, where 601 (2.58%) had HF, who were matched to 1803 non-HF patients. Among 1361 patients who underwent CAS, 87 (6.38%) had HF and were matched to 222 non-HF counterparts. Patients with HF had a much higher comorbidity burden. After CEA, patients with HF had higher risks of stroke/mortality (4.83% vs 2.55%; P = .01), cardiac (6.66% vs 3.38%; P < .01), pulmonary (4.49% vs 2.44%; P = .02), and renal complications (1.66% vs 0.44%; P = .01), as well as sepsis (1.50% vs 0.44%; P = .02), distal embolization (0.50% vs 0.00%; P = .02), unplanned operation (5.99% vs 3.49%; P = .01), prolonged hospital stay (P < .01), and 30-day readmission (13.14% vs 8.65%; P < .01). After CAS, patients with HF had similarly high risks of stroke/mortality (5.75% vs 3.60%; P = .53). CONCLUSIONS: For newly diagnosed and/or decompensated patients with HF and asymptomatic carotid stenosis, the 30-day postoperative stroke/mortality risks after both CEA and CAS greatly exceed the Society for Vascular Surgery guideline recommendations. Coupled with the substantially higher risk of other major complications, the decision to pursue surgical revascularization in asymptomatic patients with HF should be approached with extreme caution, and conservative management may be prioritized.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Li R, Sidawy AN, Nguyen BH, et al. Thirty-day stroke/mortality of carotid revascularization in asymptomatic patients with newly diagnosed and/or decompensated heart failure exceeds the Society for Vascular Society guideline risks. J Vasc Surg. 2025. PMID: 39837356. doi:10.1016/j.jvs.2025.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。